Lupin Limited announced on Thursday the launch of its generic cancer treatment drug in the US market. The Mumbai-based pharmaceutical firm has introduced Doxorubicin Hydrochloride Liposome Injection in single-dose vials.

This launch follows the approval from the US Food and Drug Administration (FDA) received by Lupin’s alliance partner, ForDoz Pharma Corporation, USA. The newly introduced product is a generic version of Baxter Healthcare Corporation’s Doxil, a well-known treatment for ovarian cancer, AIDS-related Kaposi’s Sarcoma, and multiple myeloma.

Lupin’s move expands its oncology portfolio and underscores its commitment to providing affordable, high-quality treatment options in the competitive US market.